Biogen, AbbVie pull multiple sclerosis drug from market amid safety concerns
March 02, 2018 at 13:53 PM EST
The move came after European regulators flagged eight cases in which patients who took the drug developed brain inflammation.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.